Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$2.43 USD
+0.34 (16.27%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $2.44 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GANX 2.43 +0.34(16.27%)
Will GANX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GANX
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
Alpine Immune Sciences (ALPN) Moves 10.4% Higher: Will This Strength Last?
Other News for GANX
Predictive Oncology, Augmedix, Cue Health among healthcare movers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)